Posted by Michael Wonder on 22 Jul 2021
RareStone announces submission of new drug application of Wakix (pitolisant) for narcolepsy with and without cataplexy in China
21 July 2021 - Application is supported by data used in the Wakix EMA and the U.S. FDA approvals.
RareStone, formerly Citrine Medicine, today announced its submission of a new drug application for Wakix (pitolisant).
Wakix will be considered for approval in the treatment of narcolepsy with and without cataplexy in Greater China.
